Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONSTANCE: Faricimab extended dosing interval in neovascular age-related macular degeneration
CTR20251432Phase 4Active
- Sponsor
- Roche
- Start
- May 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of faricimab in exudative macular degeneration, sponsored by Roche. Started May 2025; status: active.
02
Drugs
faricimab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20251432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251432.